Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Complementary and Alternative Medicine

Fig. 4

From: Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site

Fig. 4

Caerin 1.1 and Caerin 1.9 inhibit TC-1 growth in vivo Groups of five C57/BL6 mice were subcutaneously transplanted with 2 × 105 TC-1 tumour cells. When tumour size reached 3 mm, 30 μg of Caerin 1.1 (F1) and Caerin 1.9 (F3), or 30 μg of control peptide P3 was injected directly into tumour once per day for 7 consecutive days. Control group received PBS. Tumour growth were monitored every 3 days. Four days after final injection, tumours were isolated from individual mice and weighed. a: tumour growth curve; b: tumour weight. Groups of five C57/BL6 mice (c) or Nude mice (d) were subcutaneously transplanted with 2 × 105 of TC-1 tumour cells. When tumour size reaches to 3 mm, 30 μg of Caerin 1.1 (F1) and Caerin 1.9 (F3), 50 μg of imiquimod, or same amounts of imiquimod and Caerin peptides were injected directly into tumour one time per day for consecutively 7 days. Control group received PBS. 4 days after final injection, tumours were isolated from individual mice and weighed. Results were pooled from two independent experiments. (e): Four groups of ten C57/BL6 mice were subcutaneously transplanted with 2 × 105 of TC-1 tumour cells. 4 days after tumour inoculation, two groups were immunised twice 7 days apart with Ex/MPLA/anti-IL-10 receptor antibodies as described in Material and Methods. One day after the primary immunisation, mice were either injected for 7 consecutive days with 30 μg of caerin 1.1 and caerin 1.9 or PBS. The survival of tumour bearing mice were monitored. The results represent pooled data collected from two independent experiments. (f): Three groups of fourteen C57/BL6 mice were subcutaneously transplanted with 2 × 105 of TC-1 tumour cells. Four days after tumour inoculation, two groups were immunized twice, 7 days apart, with Ex/MPLA/ Anti-IL-10 receptor antibody described above, or with Ex/MPLA only. Control group with PBS only. One day after the primary immunisation, mice were either injected for 7 consecutive days with 30 μg of caerin 1.1 and 1.9 or PBS. The survival of tumour bearing mice were monitored.

Back to article page